Acalabrutinib (Calquence®) for CLL. HTA ID: 25040

Assessment Status Rapid Review Complete
HTA ID 25040
Drug Acalabrutinib
Brand Calquence®
Indication Acalabrutinib is indicated in combination with venetoclax with or without obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
Assessment Process
Rapid review commissioned 30/06/2025
Rapid review completed 16/07/2025
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of acalabrutinib compared with the current standard of care.

*The Applicant is seeking reimbursement for a subpopulation of the licensed population, specifically for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia excluding those with del(17p)/TP53 mutation.